Free Trial

Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis

Apellis Pharmaceuticals logo
$17.98 +0.17 (+0.93%)
Closing price 07/3/2025 03:48 PM Eastern
Extended Trading
$17.93 -0.05 (-0.31%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Apellis Pharmaceuticals Stock (NASDAQ:APLS)

Key Stats

Today's Range
$17.73
$18.26
50-Day Range
$16.36
$20.34
52-Week Range
$16.10
$42.47
Volume
891,120 shs
Average Volume
2.35 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.79
Consensus Rating
Moderate Buy

Company Overview

Apellis Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

APLS MarketRank™: 

Apellis Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 112th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 11 buy ratings, 9 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Apellis Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Apellis Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.70) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Apellis Pharmaceuticals is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Apellis Pharmaceuticals is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Apellis Pharmaceuticals has a P/B Ratio of 9.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Apellis Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    21.39% of the float of Apellis Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Apellis Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Apellis Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Apellis Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    21.39% of the float of Apellis Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Apellis Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Apellis Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 36 news articles for Apellis Pharmaceuticals this week, compared to 9 articles on an average week.
  • Search Interest

    Only 7 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $93,850.00 in company stock.

  • Percentage Held by Insiders

    Only 6.50% of the stock of Apellis Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Apellis Pharmaceuticals' insider trading history.
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Stock News Headlines

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $26.00
The #1 AI Energy Stock
Nearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being built now will dwarf everything that came before them. Thanks to AI's ravenous hunger for power … They are beginning to morph into sprawling behemoths.
Wedbush Predicts Lower Earnings for Apellis Pharmaceuticals
Zacks Research Has Bullish Estimate for APLS Q3 Earnings
Apellis Pharmaceuticals Secures $275M Royalty Buy-Down Deal
See More Headlines

APLS Stock Analysis - Frequently Asked Questions

Apellis Pharmaceuticals' stock was trading at $31.91 on January 1st, 2025. Since then, APLS stock has decreased by 43.6% and is now trading at $17.9850.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.38. The company's quarterly revenue was down 3.2% compared to the same quarter last year.
Read the conference call transcript
.

Apellis Pharmaceuticals subsidiaries include these companies: Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and more.

Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/07/2025
Today
7/05/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
770
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$39.79
High Stock Price Target
$83.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+121.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
21 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$197.88 million
Pretax Margin
-28.66%

Debt

Sales & Book Value

Annual Sales
$781.37 million
Price / Cash Flow
N/A
Book Value
$1.84 per share
Price / Book
9.77

Miscellaneous

Free Float
117,513,000
Market Cap
$2.26 billion
Optionable
Optionable
Beta
0.67

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:APLS) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners